Majid joined Janux in June 2022 as executive director and head of clinical biomarkers responsible to devise strategy, source best technology and platforms and execute comprehensive laboratory testing plans in support of Janux clinical studies. Majid has over 15 years of experience in some of the most challenging areas of oncology therapeutics with a primary focus on predictive oncology clinical development. Trained as a translational pathologist he has held impactful positions with increasing responsibilities at large pharmaceutical and small to medium biotech companies including Novartis, Celgene, Juno Therapeutics, Five Prime, and Poseida Therapeutics.
Majid has a Doctor of Veterinary Medicine degree, a postgraduate diploma and a PhD from the University of Queensland in Australia.
Andrea Patton, PhD is a Senior Behavioural Epidemiologist who leads the prevalence research team within the Centre for Substance Use Research Ltd (CSUR), Glasgow, United Kingdom. Andrea has over 15 years of experience working in public health in the United Kingdom for academia, regulatory bodies and industry.
Markus Göring is Director Asset Value Management within Vattenfall Business Area Heat. Vattenfall operates several district heating grids in Germany, the Netherlands, Sweden and UK, and manages the value chain from heat production to customer sales. Markus studied Electrical Engineering at the Technical University Hamburg-Harburg, followed by a PhD on engineering of automation systems at Helmut-Schmidt University Hamburg. He started his professional career at Vattenfall in 2009. Developing as risk-based maintenance expert and driving digitalization, Markus shaped the maintenance approach within Vattenfall, for example, as program manager for the data-driven operations and maintenance program in the wind business. Since 2020 he is responsible for developing asset management and securing asset value in the heat business.
Tony Roulstone established and teaches on the Nuclear Energy Masters programme in the Department of Engineering at the University of Cambridge. His research interestsarethe economics and safety of nuclear power witha focuson Small Modular Reactors. He is leading several SMR research projects in the UK. Also, he is involved with projects on the industrialisation and the economics of fusionHe wasa visiting Professor of Nuclear Engineering at City University in Hong Kong 2012-2018.He writes for the technical press on nuclear economics and policy matters and he is leading a group on energy storage needs for the Royal Society Working Group on Energy Storage. He received his degreefrom the University of Cambridge and has spent much of his career in the nuclear and aerospace industries, starting with UKAEAworking on fast reactor systemsand including 20 yearsat Rolls-Royce where he becameManaging Directorof the Nuclear Group in 1992.Also, he was the Directorof Engineering and Projectswhen the Vanguard nuclear submarines were being delivered. He has held several corporate Rolls-Royce plc roles in bothaero-space engineering and strategictransformation.He provides consultancywidely in the engineering, technology and services sectorsand has completedseveral policy studiesfor Governmenton SMRs, and for politicians on business enterprise and on large-scale procurement.HeisaFellow of the Institution of Mechanical Engineers,an AssociateMember of the Nuclear Institute.He is an independent adviser on SMR design.
Steven Chen, MD, MBA is the Chief Medical Officer of Avelas Biosciences in La Jolla, CA, a company with a drug/device combination focused on intraoperative margin detection. He is also a surgical oncologist in San Diego, CA. Dr. Chen received his medical degree and completed general surgery and critical care residencies at the University of Michigan, followed by a surgical oncology fellowship at the John Wayne Cancer Institute. Subsequently, he was the Chief of Breast Surgery at UC Davis Medical Center, and an Associate Professor of Surgery at City of Hope National Medical Center. He serves as the Director of Surgical Oncology at OasisMD. Dr. Chen is a past President of the American Society of Breast Surgeons and serves on committees for a number of professional societies including the American Medical Association and the American College of Surgeons
20+ years in biotech/biopharma industry, with expertise in oncology and biologics: starting as a scientist (first employee of the company) developing oncolytic virus and bacteria as live biologic drug products for cancer diagnosis and immunotherapy in human and veterinarian medicine, growing along with the company from department director to Associate VP and to VP. Currently leading Phase I, II & III clinical development in the US and Europe (UK and Germany) as VP of Clinical Trial Operations. Closely interact with regulatory agencies (FDA, USDA & NIH OBA of the US, MHRA of UK, PEI of Germany, etc.), large academic (e.g. Stanford School of Medicine, UCSD & Moores Cancer Center, NIH, Dana Farber Cancer Institute/Harvard Medical School, University of Tuebingen, University of Wuerzburg, University of Leeds, University of Surrey, Institute of Cancer Research UK, etc.) and institutions (e.g., Memorial Sloan-Kettering Cancer Center, California Veterinary Specialists, University Clinic Tuebingen, Royal Marsden Hospital, Royal Surrey County Hospital, Florida Hospital, etc.), CROs, biotech and pharmaceutical companies, and key opinion leaders. Represent the company and present clinical and preclinical data in conferences and business partnership/licensing meetings.
Collaborative and outcome-based biopharmaceutical servant-leader providing 20+ years of clinical operations experience. Passionately advancing the mission of improving patients’ lives through timely and efficient execution of clinical trials. Adept at building and managing cross-functional teams comprising internal and/or external partners and CROs to meet the dynamic business needs of virtual start-ups to leading life science companies.
Certificated professional for clinical research and regulatory affairs, with over 15 years of experience in designing, conducting, and reporting clinical & medical trials for investigational therapeutic products and companion diagnostic/prognostic products.
Broad clinical and scientific knowledge and industrial experience across multiple therapeutic areas including diabetes, GI, oncology, and rheumatology. Experience in working with both small molecules and biologic agents.
Track record in executing and overseeing clinical studies from early phase to large-scale global registrational trials (phase I to IV), including clinical reporting and regulatory submissions that have led to successful market approvals in multiple products.
Accomplished in mid-sized to large pharmaceutical corporations, with ability to balance corporate obligations with day-to-day responsibilities of developing effective and safe new therapies and clinical tools.
Tessa works closely with clients to enhance their productivity, protect their products and build loyalty with customers by designing industry 4.0 and connected packaging strategies. Due to her significant contributions in this area, she received the award for Digital Growth and Innovation from Dover Corporation in 2020. She sits on the Board of Directors of the Customer Experience Graduate Program at Seton Hall University, New Jersey; and holds an MBA in Finance from Wayne State University in Detroit, Michigan.
Dr. William Jackson, PhD is a chemist who studied at Imperial College and MIT. Subsequently, he worked for 10 years in medicinal chemistry research followed by 10 years developing processes in the generic pharmaceutical industry. Since 2000 Dr. Jackson has been working in contract R&D for a variety of clients and, since 2017, with he has worked with Zanoprima Lifesciences, where he is now the Director of Development and Manufacturing.
